GTC Nutrition Report issue

Contributed to NME For profit Phase 2
Founded: Golden CO United States (1988)
Status: No NME R&D (1988)

Organization Overview

First Clinical Trial
2009
NCT01005927
First Marketed Drug
2009
antithrombin (Recombinant) (ATryn)
First NDA Approval
2009
antithrombin (Recombinant) (ATryn)
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Marketed Drugs (1)

antithrombin (Recombinant) (ATryn) (2009 NDA)

Drugs in Phase 2 Trials (1)

fructo-oligosaccharide (1 trial)

Drugs in Other Trials (2)

galactooligosaccharide (2 trials)

sucrose (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoporosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3